(thirdQuint)TAXUS PERSEUS Workhorse.

 This is a prospective, 3:1 randomization, multi-center trial to assess the TAXUS(R) Element cent Paclitaxel-Eluting Coronary Stent System for the treatment of de novo atherosclerotic lesions of up to 28 mm in length in native coronary arteries 2.

75 mm and 4.

0 mm in diameter, compared to a control group of TAXUS Express2 Paclitaxel-Eluting Coronary Stent System .

 One thousand two hundred sixty-four (1264) subjects will be treated with either the TAXUS(R) Element cent stent or the TAXUS(R) Express2 cent stent at a maximum of 100 clinical sites.

 Randomization to treatment group will be unbalanced 3:1 towards the test group to gain maximum clinical experience with the new TAXUS(R) Element cent platform.

 Follow-up at 30 days, 9 months and 12 months will be completed in all subjects enrolled in the study.

 Angiographic follow-up at 9 months will be completed in a subset of three hundred thirty (330) subjects enrolled in the study.

 Subjects will be randomly allocated to the angiographic subset at participating sites through the Interactive Voice Response System (IVRS).

 Eligible subjects will have annual follow-up until 5 years post-index procedure.

.

 TAXUS PERSEUS Workhorse@highlight

The purpose of the TAXUS PERSEUS Workhorse trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS(R) ElementTM) for the treatment of de novo atherosclerotic lesions of up to 28 mm in length in native coronary arteries of 2.

75 mm to 4.

0 mm diameter.

